Niox Group PLC
LSE:NIOX

Watchlist Manager
Niox Group PLC Logo
Niox Group PLC
LSE:NIOX
Watchlist
Price: 64.2 GBX -1.53% Market Closed
Market Cap: 255.5m GBX
Have any thoughts about
Niox Group PLC?
Write Note

Niox Group PLC
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Niox Group PLC
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Niox Group PLC
LSE:NIOX
Pre-Tax Income
ÂŁ5.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Pre-Tax Income
-$176.1m
CAGR 3-Years
-155%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Pre-Tax Income
-$208.4m
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Pre-Tax Income
-$169.6m
CAGR 3-Years
-36%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Pre-Tax Income
-ÂŁ60.9m
CAGR 3-Years
11%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Pre-Tax Income
ÂŁ5.5m
CAGR 3-Years
-54%
CAGR 5-Years
-11%
CAGR 10-Years
-18%
No Stocks Found

Niox Group PLC
Glance View

Market Cap
272.2m GBX
Industry
Biotechnology

Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.

NIOX Intrinsic Value
48.29 GBX
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Niox Group PLC's Pre-Tax Income?
Pre-Tax Income
5.6m GBP

Based on the financial report for Jun 30, 2024, Niox Group PLC's Pre-Tax Income amounts to 5.6m GBP.

What is Niox Group PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 1Y
24%

Over the last year, the Pre-Tax Income growth was 24%.

Back to Top